Loading…

The association between metabolic abnormality and endometrial cancer: A large case-control study in China

Abstract Objectives. To investigate the association between insulin-resistance-related conditions (comprising the metabolic syndrome) and endometrial cancer risk in Chinese women. Methods. We conducted a large case-control study including 942 endometrial cancers and 1721 controls on a Chinese popula...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2010-04, Vol.117 (1), p.41-46
Main Authors: Zhang, Yan, Liu, Zhiwei, Yu, Xinchun, Zhang, Xiaofei, Lü, Shiming, Chen, Xiaoduan, Lü, Bingjian
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3
cites cdi_FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3
container_end_page 46
container_issue 1
container_start_page 41
container_title Gynecologic oncology
container_volume 117
creator Zhang, Yan
Liu, Zhiwei
Yu, Xinchun
Zhang, Xiaofei
Lü, Shiming
Chen, Xiaoduan
Lü, Bingjian
description Abstract Objectives. To investigate the association between insulin-resistance-related conditions (comprising the metabolic syndrome) and endometrial cancer risk in Chinese women. Methods. We conducted a large case-control study including 942 endometrial cancers and 1721 controls on a Chinese population. The relative endometrial cancer risks from various factors were calculated by the х2 test. Menopausal status and BMI were applied as potential confounders to analyze the joint effects with other factors. Results. We found that overweight/obesity, hypertension, diabetes mellitus and glucose metabolic disturbance were all associated with endometrial cancer risk. Effective medication on diabetes can significantly decrease cancer risk (uncontrolled diabetes: RR = 5.563, 95% CI = 2.406–12.859, p < 0.001; controlled diabetes: RR = 1.331, 95% CI = 0.529–3.352, p > 0.05) as compared with normal controls. Serum lipids were also found to be linked to endometrial cancer risk: positive correlations were present with total serum cholesterol, triglycerides, low-density lipoprotein cholesterol and dyslipidaemia, while a negative correlation was found with high-density lipoprotein cholesterol. We also observed an elevated risk for type I endometrial cancer (OR = 1.839, 95% CI = 1.539–2.197, p < 0.001) in women with BMI ≥ 24.58 versus those with BMI < 24.58, but not for type II cancer (OR = 1.092, 95% CI = 0.969–1.231, p > 0.05). Conclusions. Our findings support the hypothesis that metabolic abnormalities or insulin resistance may promote the initiation and progression of endometrial cancer. The effective treatment of type 2 diabetes might contribute to endometrial cancer prevention.
doi_str_mv 10.1016/j.ygyno.2009.12.029
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733802672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0090825810000041</els_id><sourcerecordid>733802672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7uzqLxAkN0_d5mP6S1BYBl2FBQ-u55CuVO9mTCdrklb635t2Vg9ezCWEep8q8hQhLzirOePt62O93q4-1IKxoeaiZmJ4RHacDU3V9s3wmOxKgVW9aPozcp7SkTEmGRdPydmGtIPgO2Jv7pDqlAJYnW3wdMT8E9HTGbMeg7NA9ehDnLWzeaXaG4rehFKNVjsK2gPGN_SSOh1vsbwTVhB8jsHRlBezUuvp4c56_Yw8mbRL-PzhviBfP7y_OXysrj9ffTpcXlew74ZcTa0EqRFM22icJtntm1b3-1agMWPDcOxBQsOl6AcpGPBmNDAxmDrU2EqJ8oK8OvW9j-H7gimr2SZA57THsCTVSdkz0XaiJOUpCTGkFHFS99HOOq6KM7UpVkf1W7HafCkuVFFcqJcP_ZdxRvOX-eO0BN6eAlh--cNiVAksFk_GRoSsTLD_GfDuHx6c9Ra0-4YrpmNYoi8CFVepAOrLtuVtyZxtZ8_lL2JNpQ8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733802672</pqid></control><display><type>article</type><title>The association between metabolic abnormality and endometrial cancer: A large case-control study in China</title><source>ScienceDirect Freedom Collection</source><creator>Zhang, Yan ; Liu, Zhiwei ; Yu, Xinchun ; Zhang, Xiaofei ; Lü, Shiming ; Chen, Xiaoduan ; Lü, Bingjian</creator><creatorcontrib>Zhang, Yan ; Liu, Zhiwei ; Yu, Xinchun ; Zhang, Xiaofei ; Lü, Shiming ; Chen, Xiaoduan ; Lü, Bingjian</creatorcontrib><description>Abstract Objectives. To investigate the association between insulin-resistance-related conditions (comprising the metabolic syndrome) and endometrial cancer risk in Chinese women. Methods. We conducted a large case-control study including 942 endometrial cancers and 1721 controls on a Chinese population. The relative endometrial cancer risks from various factors were calculated by the х2 test. Menopausal status and BMI were applied as potential confounders to analyze the joint effects with other factors. Results. We found that overweight/obesity, hypertension, diabetes mellitus and glucose metabolic disturbance were all associated with endometrial cancer risk. Effective medication on diabetes can significantly decrease cancer risk (uncontrolled diabetes: RR = 5.563, 95% CI = 2.406–12.859, p &lt; 0.001; controlled diabetes: RR = 1.331, 95% CI = 0.529–3.352, p &gt; 0.05) as compared with normal controls. Serum lipids were also found to be linked to endometrial cancer risk: positive correlations were present with total serum cholesterol, triglycerides, low-density lipoprotein cholesterol and dyslipidaemia, while a negative correlation was found with high-density lipoprotein cholesterol. We also observed an elevated risk for type I endometrial cancer (OR = 1.839, 95% CI = 1.539–2.197, p &lt; 0.001) in women with BMI ≥ 24.58 versus those with BMI &lt; 24.58, but not for type II cancer (OR = 1.092, 95% CI = 0.969–1.231, p &gt; 0.05). Conclusions. Our findings support the hypothesis that metabolic abnormalities or insulin resistance may promote the initiation and progression of endometrial cancer. The effective treatment of type 2 diabetes might contribute to endometrial cancer prevention.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2009.12.029</identifier><identifier>PMID: 20096921</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Body Mass Index ; Case-Control Studies ; China - epidemiology ; Diabetes mellitus ; Diabetes Mellitus - epidemiology ; Diabetes Mellitus - metabolism ; Endometrial cancer ; Endometrial Neoplasms - epidemiology ; Endometrial Neoplasms - metabolism ; Endometrial Neoplasms - pathology ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Hypertension - epidemiology ; Hypertension - metabolism ; Menopause ; Metabolic syndrome ; Metabolic Syndrome - epidemiology ; Metabolic Syndrome - metabolism ; Neoplasm Staging ; Obesity ; Obstetrics and Gynecology ; Risk Factors ; Serum lipid</subject><ispartof>Gynecologic oncology, 2010-04, Vol.117 (1), p.41-46</ispartof><rights>Elsevier Inc.</rights><rights>2010 Elsevier Inc.</rights><rights>Copyright 2010 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3</citedby><cites>FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20096921$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Liu, Zhiwei</creatorcontrib><creatorcontrib>Yu, Xinchun</creatorcontrib><creatorcontrib>Zhang, Xiaofei</creatorcontrib><creatorcontrib>Lü, Shiming</creatorcontrib><creatorcontrib>Chen, Xiaoduan</creatorcontrib><creatorcontrib>Lü, Bingjian</creatorcontrib><title>The association between metabolic abnormality and endometrial cancer: A large case-control study in China</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Abstract Objectives. To investigate the association between insulin-resistance-related conditions (comprising the metabolic syndrome) and endometrial cancer risk in Chinese women. Methods. We conducted a large case-control study including 942 endometrial cancers and 1721 controls on a Chinese population. The relative endometrial cancer risks from various factors were calculated by the х2 test. Menopausal status and BMI were applied as potential confounders to analyze the joint effects with other factors. Results. We found that overweight/obesity, hypertension, diabetes mellitus and glucose metabolic disturbance were all associated with endometrial cancer risk. Effective medication on diabetes can significantly decrease cancer risk (uncontrolled diabetes: RR = 5.563, 95% CI = 2.406–12.859, p &lt; 0.001; controlled diabetes: RR = 1.331, 95% CI = 0.529–3.352, p &gt; 0.05) as compared with normal controls. Serum lipids were also found to be linked to endometrial cancer risk: positive correlations were present with total serum cholesterol, triglycerides, low-density lipoprotein cholesterol and dyslipidaemia, while a negative correlation was found with high-density lipoprotein cholesterol. We also observed an elevated risk for type I endometrial cancer (OR = 1.839, 95% CI = 1.539–2.197, p &lt; 0.001) in women with BMI ≥ 24.58 versus those with BMI &lt; 24.58, but not for type II cancer (OR = 1.092, 95% CI = 0.969–1.231, p &gt; 0.05). Conclusions. Our findings support the hypothesis that metabolic abnormalities or insulin resistance may promote the initiation and progression of endometrial cancer. The effective treatment of type 2 diabetes might contribute to endometrial cancer prevention.</description><subject>Body Mass Index</subject><subject>Case-Control Studies</subject><subject>China - epidemiology</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Diabetes Mellitus - metabolism</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - epidemiology</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Hypertension - epidemiology</subject><subject>Hypertension - metabolism</subject><subject>Menopause</subject><subject>Metabolic syndrome</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Metabolic Syndrome - metabolism</subject><subject>Neoplasm Staging</subject><subject>Obesity</subject><subject>Obstetrics and Gynecology</subject><subject>Risk Factors</subject><subject>Serum lipid</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqFkU2LFDEQhoMo7uzqLxAkN0_d5mP6S1BYBl2FBQ-u55CuVO9mTCdrklb635t2Vg9ezCWEep8q8hQhLzirOePt62O93q4-1IKxoeaiZmJ4RHacDU3V9s3wmOxKgVW9aPozcp7SkTEmGRdPydmGtIPgO2Jv7pDqlAJYnW3wdMT8E9HTGbMeg7NA9ehDnLWzeaXaG4rehFKNVjsK2gPGN_SSOh1vsbwTVhB8jsHRlBezUuvp4c56_Yw8mbRL-PzhviBfP7y_OXysrj9ffTpcXlew74ZcTa0EqRFM22icJtntm1b3-1agMWPDcOxBQsOl6AcpGPBmNDAxmDrU2EqJ8oK8OvW9j-H7gimr2SZA57THsCTVSdkz0XaiJOUpCTGkFHFS99HOOq6KM7UpVkf1W7HafCkuVFFcqJcP_ZdxRvOX-eO0BN6eAlh--cNiVAksFk_GRoSsTLD_GfDuHx6c9Ra0-4YrpmNYoi8CFVepAOrLtuVtyZxtZ8_lL2JNpQ8</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Zhang, Yan</creator><creator>Liu, Zhiwei</creator><creator>Yu, Xinchun</creator><creator>Zhang, Xiaofei</creator><creator>Lü, Shiming</creator><creator>Chen, Xiaoduan</creator><creator>Lü, Bingjian</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100401</creationdate><title>The association between metabolic abnormality and endometrial cancer: A large case-control study in China</title><author>Zhang, Yan ; Liu, Zhiwei ; Yu, Xinchun ; Zhang, Xiaofei ; Lü, Shiming ; Chen, Xiaoduan ; Lü, Bingjian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Body Mass Index</topic><topic>Case-Control Studies</topic><topic>China - epidemiology</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Diabetes Mellitus - metabolism</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - epidemiology</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Hypertension - epidemiology</topic><topic>Hypertension - metabolism</topic><topic>Menopause</topic><topic>Metabolic syndrome</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Metabolic Syndrome - metabolism</topic><topic>Neoplasm Staging</topic><topic>Obesity</topic><topic>Obstetrics and Gynecology</topic><topic>Risk Factors</topic><topic>Serum lipid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Liu, Zhiwei</creatorcontrib><creatorcontrib>Yu, Xinchun</creatorcontrib><creatorcontrib>Zhang, Xiaofei</creatorcontrib><creatorcontrib>Lü, Shiming</creatorcontrib><creatorcontrib>Chen, Xiaoduan</creatorcontrib><creatorcontrib>Lü, Bingjian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yan</au><au>Liu, Zhiwei</au><au>Yu, Xinchun</au><au>Zhang, Xiaofei</au><au>Lü, Shiming</au><au>Chen, Xiaoduan</au><au>Lü, Bingjian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The association between metabolic abnormality and endometrial cancer: A large case-control study in China</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>117</volume><issue>1</issue><spage>41</spage><epage>46</epage><pages>41-46</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Abstract Objectives. To investigate the association between insulin-resistance-related conditions (comprising the metabolic syndrome) and endometrial cancer risk in Chinese women. Methods. We conducted a large case-control study including 942 endometrial cancers and 1721 controls on a Chinese population. The relative endometrial cancer risks from various factors were calculated by the х2 test. Menopausal status and BMI were applied as potential confounders to analyze the joint effects with other factors. Results. We found that overweight/obesity, hypertension, diabetes mellitus and glucose metabolic disturbance were all associated with endometrial cancer risk. Effective medication on diabetes can significantly decrease cancer risk (uncontrolled diabetes: RR = 5.563, 95% CI = 2.406–12.859, p &lt; 0.001; controlled diabetes: RR = 1.331, 95% CI = 0.529–3.352, p &gt; 0.05) as compared with normal controls. Serum lipids were also found to be linked to endometrial cancer risk: positive correlations were present with total serum cholesterol, triglycerides, low-density lipoprotein cholesterol and dyslipidaemia, while a negative correlation was found with high-density lipoprotein cholesterol. We also observed an elevated risk for type I endometrial cancer (OR = 1.839, 95% CI = 1.539–2.197, p &lt; 0.001) in women with BMI ≥ 24.58 versus those with BMI &lt; 24.58, but not for type II cancer (OR = 1.092, 95% CI = 0.969–1.231, p &gt; 0.05). Conclusions. Our findings support the hypothesis that metabolic abnormalities or insulin resistance may promote the initiation and progression of endometrial cancer. The effective treatment of type 2 diabetes might contribute to endometrial cancer prevention.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20096921</pmid><doi>10.1016/j.ygyno.2009.12.029</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 2010-04, Vol.117 (1), p.41-46
issn 0090-8258
1095-6859
language eng
recordid cdi_proquest_miscellaneous_733802672
source ScienceDirect Freedom Collection
subjects Body Mass Index
Case-Control Studies
China - epidemiology
Diabetes mellitus
Diabetes Mellitus - epidemiology
Diabetes Mellitus - metabolism
Endometrial cancer
Endometrial Neoplasms - epidemiology
Endometrial Neoplasms - metabolism
Endometrial Neoplasms - pathology
Female
Hematology, Oncology and Palliative Medicine
Humans
Hypertension - epidemiology
Hypertension - metabolism
Menopause
Metabolic syndrome
Metabolic Syndrome - epidemiology
Metabolic Syndrome - metabolism
Neoplasm Staging
Obesity
Obstetrics and Gynecology
Risk Factors
Serum lipid
title The association between metabolic abnormality and endometrial cancer: A large case-control study in China
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A05%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20association%20between%20metabolic%20abnormality%20and%20endometrial%20cancer:%20A%20large%20case-control%20study%20in%20China&rft.jtitle=Gynecologic%20oncology&rft.au=Zhang,%20Yan&rft.date=2010-04-01&rft.volume=117&rft.issue=1&rft.spage=41&rft.epage=46&rft.pages=41-46&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2009.12.029&rft_dat=%3Cproquest_cross%3E733802672%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733802672&rft_id=info:pmid/20096921&rfr_iscdi=true